In addition, Raf-1 is an effector of the protein product of the ras oncogene [91], which is often found to be mutated in malignantly transformed cells; this is why therapy directed at suppressing raf-1 can prove to be effective against ras-mediated neoplasias. The gene discussed is RAF1; the disease is neoplasm.